Product information and disease descriptionProduct descriptionProduct informationPharmacology
Mechanism of action
9 evidence topics · 12 sources
Pan-PPAR agonist: company description of isoform activation
Company rationale for activating all three isoforms
Chemical class: indole sulfonamide small molecule
“Here, we describe the identification and synthesis of novel indole sulfonamide derivatives that activate the three peroxisome proliferator activated receptor (PPAR) isoforms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Starting with a PPARα activator, compound 4, identified during a high throughput screening (HTS) of our proprietary screening library, a systematic optimization led to the discovery of lanifibranor (IVA337) 5, a moderately potent and well balanced pan PPAR agonist with an excellent safety profile.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Transactivation potency and maximal effect at human PPAR isoforms
“In the transactivation assay (see Supporting Information), IVA337 acts as a pan‐PPAR agonist with moderate and balanced activity on the three PPAR isoforms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“IVA337 50% effective concentration (EC50) levels for the human PPARs (hPPARs) were 1.63E‐06 M for PPARα, 8.49E‐07 M for PPARδ, and 2.28E‐07 M for PPARγ.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The maximal effect (Emax) reached 100% for both hPPARα and hPPARδ and 80% for hPPARγ when compared to fenofibrate, GW501516, and rosiglitazone, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The potency of IVA337 for PPARα and PPARγ is in the same range as that of fenofibrate (EC50, 2 µM; PPARα) and pioglitazone (EC50, 0.3 µM; PPARγ), two clinically used and well‐tolerated PPAR agonists with a good efficacy/safety ratio.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Isoform potency and PPARγ efficacy relative to pioglitazone
“This study was designed so as to provide functional and structural insights into the potency, efficacy, and selectivity against PPARα/δ/γ of lanifibranor, seladelpar, and elafibranor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The EC50 values for PPARα/δ/γ were in small ranges (0.4–5 µM in Figure 1B and 3–14 µM in Figure 2A,B), and therefore, lanifibranor in clinical doses seems to be able to activate all PPAR subtypes at once.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to the fact that its efficacies for PPARγ activation often match with those of pioglitazone (Figure 2A vs. Figure 2I, Figure 2B vs. Figure 2J, and Figure 3B vs. Figure 3F), PPARγ-related undesirable side effects (such as weight gain, edema, bone loss, and congestive heart failure) [42] should be closely monitored in the case of lanifibranor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Isoform-specific pathways attributed to each PPAR subtype
“Among other effects, PPARα agonists reduce TG levels by increasing mitochondrial FA β-oxidation; PPARβ/δ ligands increase HDL-C levels, have anti-inflammatory effects and improve glucose utilization of skeletal muscle, while PPARγ activity exerts antifibrotic effects on activated hepatic stellate cells and improves IS in liver, adipose tissue and skeletal muscle.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The clinical metabolic-immune improvements with lanifibranor indeed substantiate the pan-PPAR activating mechanism across all three subtypes, exemplified by the effects on TG, HDL-C and IR reflecting mainly PPARα, β/δ and γ mediated mechanisms, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preclinical efficacy compared with single and dual PPAR agonists
Hepatic stellate cell proliferation and activation
“IVA337 dose dependently and completely inhibited PDGF‐induced hHSC proliferation (Fig. 7A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, the selective PPAR agonists demonstrated only partial effects up to the highest concentrations (Fig. 7A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatic macrophage activation: PPARδ-dependent effect
“Lanifibranor attenuated the accompanying inflammatory activation in both murine palmitic acid-stimulated bone marrow-derived macrophages, as well as patient-derived circulating monocytes, in a PPARδ-dependent fashion.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“PPARδ agonism and lanifibranor directly modulate macrophage activation, but not infiltration, thereby synergizing with beneficial metabolic effects of PPARα/γ agonists.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote